Non-steroidal intravitreal injection for noninfectious uveitic cystoid macular edema: Systematic review and meta-analysis.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

European Journal of Ophthalmology Pub Date : 2024-09-01 Epub Date: 2023-11-06 DOI:10.1177/11206721231212777

Farzan Kianersi, Abdolreza Rezaeian-Ramsheh, Alireza Rahimi, Mohammadreza Akhlaghi, Alireza Dehghani, Ziba Farajzadegan, Mohsen Pourazizi

{"title":"Non-steroidal intravitreal injection for noninfectious uveitic cystoid macular edema: Systematic review and meta-analysis.","authors":"Farzan Kianersi, Abdolreza Rezaeian-Ramsheh, Alireza Rahimi, Mohammadreza Akhlaghi, Alireza Dehghani, Ziba Farajzadegan, Mohsen Pourazizi","doi":"10.1177/11206721231212777","DOIUrl":null,"url":null,"abstract":"Purpose: To systematically review the published manuscripts on the non-steroidal intravitreal injection for treatment of noninfectious uveitic cystoid macular edema (CME).Methods: The PubMed, Scopus, and Web of Science, Science Direct, ProQuest, Cochrane Library, ProQuest, Embase, Clinical Key, and Springer were searched for relevant articles published until May 2022. The random-effects models were used to estimate the mean difference (MD) and 95% confidence interval (CI) for postoperative central macular thickness (CMT) and visual acuity (VA) changes. VA was transformed into the logarithm of the minimum angle of resolution (LogMAR). Meta-regression was conducted for adjusting the effects of potential confounders.Results: A total of 17 relevant studies (258 eyes) were included in this meta-analysis. A significant improvement was observed in CMT in the last follow up (350.89 ± 108.43) compared to the baseline (452.3 ± 112.67) (Log MD = 1.82, 95% CI = 1.62, 2.02; I2 = 57.7%; P = 0.002). Additionally, VA also significantly improved in the last follow up (0.56 ± 0.29) compared to the baseline (0.75 ± 0.3) (Exponential MD = 0.82, 95% CI = 0.69, 0.95; I2 = 0.0%; P = 0.98). The subgroups analyzed included ten studies on anti-vascular endothelial growth factors (VEGF), three studies on infliximab, two studies on methotrexate (MTX), and two studies on diclofenac. All subgroups showed a significant improvement in both CMT and VA at the last follow-up (P < 0.05).Conclusion: Non-steroidal intravitreal injection including bevacizumab, ranibizumab, infliximab, MTX and diclofenac appears to be an effective treatment option for noninfectious uveitic CME.","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721231212777","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To systematically review the published manuscripts on the non-steroidal intravitreal injection for treatment of noninfectious uveitic cystoid macular edema (CME).

Methods: The PubMed, Scopus, and Web of Science, Science Direct, ProQuest, Cochrane Library, ProQuest, Embase, Clinical Key, and Springer were searched for relevant articles published until May 2022. The random-effects models were used to estimate the mean difference (MD) and 95% confidence interval (CI) for postoperative central macular thickness (CMT) and visual acuity (VA) changes. VA was transformed into the logarithm of the minimum angle of resolution (LogMAR). Meta-regression was conducted for adjusting the effects of potential confounders.

Results: A total of 17 relevant studies (258 eyes) were included in this meta-analysis. A significant improvement was observed in CMT in the last follow up (350.89 ± 108.43) compared to the baseline (452.3 ± 112.67) (Log MD = 1.82, 95% CI = 1.62, 2.02; I2 = 57.7%; P = 0.002). Additionally, VA also significantly improved in the last follow up (0.56 ± 0.29) compared to the baseline (0.75 ± 0.3) (Exponential MD = 0.82, 95% CI = 0.69, 0.95; I² = 0.0%; P = 0.98). The subgroups analyzed included ten studies on anti-vascular endothelial growth factors (VEGF), three studies on infliximab, two studies on methotrexate (MTX), and two studies on diclofenac. All subgroups showed a significant improvement in both CMT and VA at the last follow-up (P < 0.05).

Conclusion: Non-steroidal intravitreal injection including bevacizumab, ranibizumab, infliximab, MTX and diclofenac appears to be an effective treatment option for noninfectious uveitic CME.

查看原文本刊更多论文

非甾体玻璃体内注射治疗非感染性葡萄膜炎囊样黄斑水肿：系统综述和荟萃分析。

目的：系统回顾已发表的非甾体玻璃体内注射治疗非感染性葡萄膜炎囊样黄斑水肿（CME）的文献。方法：检索PubMed、Scopus和Web of Science、Science Direct、ProQuest、Cochrane Library、ProQuesti、Embase、Clinical Key和Springer在2022年5月之前发表的相关文章。随机效应模型用于估计术后中央黄斑厚度（CMT）和视力（VA）变化的平均差（MD）和95%置信区间（CI）。VA被转换为最小分辨率角度的对数（LogMAR）。进行荟萃回归以调整潜在混杂因素的影响。结果：本荟萃分析共纳入17项相关研究（258眼）。在最后一次随访中观察到CMT有显著改善（350.89 ± 108.43）与基线（452.3 ± 112.67）（Log MD = 1.82，95%CI = 1.62、2.02；I2 = 57.7%；P = 0.002）。此外，VA在上次随访中也有显著改善（0.56 ± 0.29）与基线（0.75 ± 0.3）（指数MD = 0.82，95%CI = 0.69、0.95；I2 = 0.0%；P = 0.98）。分析的亚组包括10项关于抗血管内皮生长因子（VEGF）的研究、3项关于英夫利昔单抗的研究、2项关于甲氨蝶呤（MTX）的研究和2项关于双氯芬酸的研究。所有亚组在最后一次随访时CMT和VA均有显著改善（P 结论：非甾体玻璃体内注射，包括贝伐单抗、雷尼珠单抗、英夫利昔单抗、MTX和双氯芬酸，似乎是治疗非感染性葡萄膜炎CME的有效选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Ophthalmology 医学-眼科学

CiteScore

3.60

自引率

0.00%

发文量

372

审稿时长

3-8 weeks

期刊介绍： The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.